PAMAfrica

Portfolio approach to developing the next-generation of malaria treatments for Africa

This project is part of the EDCTP2 Programme supported by the European Union.
EDCTP
EU

Search

Search

  • About us
    • What we do
    • Governance
    • PAMAfrica scientists
    • PAMAfrica students
  • Work packages
    • Next-generation drug combination for uncomplicated malaria
    • First malaria treatment for babies under 5kg
    • New medicine for treatement of severe malaria
    • Building research capacity
  • Consortium partners
  • Newsroom
    • Resources
    • News
Search
First malaria medicine for young infants 2-5 kg receives approval

First malaria medicine for young infants 2-5 kg receives approval

Read more

First malaria medicine for young infants 2-5 kg receives approval
Coartem® Baby launches in Ghana

Coartem® Baby launches in Ghana

Read more

Coartem® Baby launches in Ghana
MMV’s Timothy Wells visits CISM researchers in Mozambique to discuss lessons and advances in malaria

Timothy Wells visits CISM researchers in Mozambique

Read more

MMV’s Timothy Wells visits CISM researchers in Mozambique to discuss lessons and advances in malaria
Delivering better healthcare outcomes through PAMAfrica’s CALINA study

Delivering better healthcare outcomes through PAMAfrica’s CALINA study

Read more

Delivering better healthcare outcomes through PAMAfrica’s CALINA study
MMV and and Novartis announce positive efficacy and safety data for a novel treatment for babies <5 kg with malaria

MMV and and Novartis announce positive efficacy and safety data for a novel treatment for babies <5 kg with malaria

Read more

MMV and and Novartis announce positive efficacy and safety data for a novel treatment for babies <5 kg with malaria
SwissCore: PAMAfrica’s role in the global fight against malaria

SwissCore: PAMAfrica’s role in the global fight against malaria

Read more

SwissCore: PAMAfrica’s role in the global fight against malaria
The Guardian: Could new malaria drug give babies a better chance of survival?

The Guardian: Could new malaria drug give babies a better chance of survival?

Read more

The Guardian: Could new malaria drug give babies a better chance of survival?

Take a look at our infographic!

Read more

Take a look at our infosheet!

Read more

Photo: Alex Radelich

Portfolio approach to developing the next-generation of malaria treatments for Africa

1

Work packages

Next-generation drug combination for uncomplicated malaria

First malaria treatment for young infants 2-5 kg

New medicine for treatment of severe malaria

Strengthening research capacity in Africa

1

PAMAfrica scientists

Dr Yeka Adoke

Ph.D, Director and Principal Investigator at IDRC (WP 1)

Miss Sarita Barsainya

Masters in Pharmacy, Global Trial Director at Novartis (WP 3)

Dr Quique Bassat

PhD, Head of the Malaria Programme at ISGlobal (WP 2)

Dr Helen Demarest

PhD, Director, Clinical Operations for MMV (WP 4)

Dr Ghyslain Mombo-Ngoma

MD, PhD, Head of Clinical Operations at CERMEL (WP 1 - WP 3)
View more profiles of our scientists

Consortium Partners

MMV

Medicines for Malaria Venture (MMV) is a leading product development partnership (PDP) in antimalarial drug research in its 20th year.

Novartis

Novartis is reimagining medicine to improve and extend people’s lives. 

Merck

Merck, a leading science and technology company, operates across life science, healthcare and electronics.

Tubingen logo

The Eberhard Karls Universität Tübingen

The Eberhard Karls Universität Tübingen is one of Europe’s oldest universities, with key strengths in Sciences and Life Sciences. Within the Faculty of Medicine, the Institute of Tropical Medicine (ITM) is an established Centre of Excellence (since 2007).

CERMEL

ISGlobal logo

ISGlobal

The ultimate goal of ISGlobal is to help close the gaps in health disparities between and within different regions of the world.

Manhiça Health Research Centre

Manhiça Health Research Centre is a research institution managed by Manhiça Foundation, whose mission is to promote and conduct biomedical research in health priority areas to promote and safeguard the health of the population.

Groupe de Recherche Action en Santé logo

GRAS

The Groupe de Recherche Action en Santé (GRAS) is a private institute based in Burkina Faso, operating since 2008 in the field of health research.

IDRC

IDRC conducts research in infectious diseases including Malaria, HIV, Tuberculosis and other diseases of public health importance through collaboration and partnership. 

CRUN

The CRUN’s mission is to provide evidence-based information for the health care of populations living in tropical countries. 

1

Resources

17 Oct 2025

PAMAfrica Infographic

Article
Prescription patterns and compliance with World Health Organization recommendations for the management of uncomplicated and severe malaria: A prospective, real-world study in sub-Saharan Africa
14 Nov 2024

Prescription patterns and compliance with World Health Organization recommendations for the management of uncomplicated and severe malaria: A prospective, real-world study in sub-Saharan Africa

Malaria Journal
Peer-reviewed article
Evolution of Pfdhps and Pfdhfr mutations before and after adopting seasonal malaria chemoprevention in Nanoro, Burkina Faso
14 Nov 2024

Evolution of Pfdhps and Pfdhfr mutations before and after adopting seasonal malaria chemoprevention in Nanoro, Burkina Faso

Scientific Reports
Peer-reviewed article
PAMAfrica training initiatives: 2020–2023
10 Sep 2024

PAMAfrica training initiatives: 2020–2023

An infographic detailing the training initiatives undertaken through PAMAfricas Work Package 4: Building research capacity in Africa
View all

Contact us

infopamafrica [at] mmv [dot] org

A Remora website by Manta Ray Media